Genomic Profiling of Cancer: What Next?
- 10 October 2005
- journal article
- editorial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (29) , 7253-7256
- https://doi.org/10.1200/jco.2005.03.9792
Abstract
No abstract availableThis publication has 28 references indexed in Scilit:
- Pharmacogenomic Discovery Approaches: Will the Real Genes Please Stand Up?Journal of Clinical Oncology, 2005
- Genomics and the second golden era of cancer drug developmentMolecular BioSystems, 2005
- EGFRMutation and Resistance of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2005
- Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase DomainPLoS Medicine, 2005
- EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinibProceedings of the National Academy of Sciences, 2004
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- High Frequency of Mutations of the PIK3CA Gene in Human CancersScience, 2004
- Mutational Analysis of the Tyrosine Kinome in Colorectal CancersScience, 2003
- Mutations of the BRAF gene in human cancerNature, 2002